Clinical Trials Browser

Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Carcinoma, Hepatocellular

Stomach Neoplasms

Malignant Neoplasms of Digestive Organs

Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms, Stomach Neoplasms

Metastatic Castration Resistant Prostate Cancer

Small Cell Lung Carcinoma

Carcinoma, Adenoid Cystic

Colorectal Neoplasms

Neoplasm Metastasis

Carcinoma, Hepatocellular

Stomach Neoplasms

Stomach Neoplasms

Neoplasm Metastasis, Neoplasms

Advanced Solid Tumor

Advanced Solid Tumor

Triple Negative Breast Neoplasms

Stomach Neoplasms

Ovarian Neoplasms, Triple Negative Breast Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms

PD-L1 Positive Non-small Cell Lung Cancer

Ovarian Neoplasms

Advanced Cancer

Recurrence, Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Clinical Trials

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

PASSION

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

Dose-Escalation and Safety Trial of YN968D1

HS:Hansoh;

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Effect of Rifampicin on the Pharmacokinetics of Apatinib

ANSWER

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer